ID28696A - Penggunaan medis suatu modulator reseptor estrogen selektif dalam kombinasi dengan prekursor-prekursor steroid kelamin - Google Patents

Penggunaan medis suatu modulator reseptor estrogen selektif dalam kombinasi dengan prekursor-prekursor steroid kelamin

Info

Publication number
ID28696A
ID28696A IDW20010032A ID20010032A ID28696A ID 28696 A ID28696 A ID 28696A ID W20010032 A IDW20010032 A ID W20010032A ID 20010032 A ID20010032 A ID 20010032A ID 28696 A ID28696 A ID 28696A
Authority
ID
Indonesia
Prior art keywords
estrogent
gold
selective
combination
medical use
Prior art date
Application number
IDW20010032A
Other languages
English (en)
Indonesian (id)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of ID28696A publication Critical patent/ID28696A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
IDW20010032A 1998-06-11 1999-06-10 Penggunaan medis suatu modulator reseptor estrogen selektif dalam kombinasi dengan prekursor-prekursor steroid kelamin ID28696A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/096,284 US6465445B1 (en) 1998-06-11 1998-06-11 Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Publications (1)

Publication Number Publication Date
ID28696A true ID28696A (id) 2001-06-28

Family

ID=22256661

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010032A ID28696A (id) 1998-06-11 1999-06-10 Penggunaan medis suatu modulator reseptor estrogen selektif dalam kombinasi dengan prekursor-prekursor steroid kelamin

Country Status (29)

Country Link
US (6) US6465445B1 (US06465445-20021015-C00002.png)
EP (5) EP1623712B1 (US06465445-20021015-C00002.png)
JP (3) JP2002517433A (US06465445-20021015-C00002.png)
KR (6) KR20090018871A (US06465445-20021015-C00002.png)
CN (2) CN1240388C (US06465445-20021015-C00002.png)
AR (1) AR043075A1 (US06465445-20021015-C00002.png)
AT (1) ATE308326T1 (US06465445-20021015-C00002.png)
AU (1) AU4253099A (US06465445-20021015-C00002.png)
BR (1) BR9911116A (US06465445-20021015-C00002.png)
CA (7) CA2768682C (US06465445-20021015-C00002.png)
CY (4) CY1113712T1 (US06465445-20021015-C00002.png)
DE (1) DE69928104T2 (US06465445-20021015-C00002.png)
DK (5) DK2386305T3 (US06465445-20021015-C00002.png)
ES (5) ES2473040T3 (US06465445-20021015-C00002.png)
HK (1) HK1040367B (US06465445-20021015-C00002.png)
HU (2) HU230495B1 (US06465445-20021015-C00002.png)
ID (1) ID28696A (US06465445-20021015-C00002.png)
IL (3) IL140178A0 (US06465445-20021015-C00002.png)
MX (1) MXPA00012306A (US06465445-20021015-C00002.png)
MY (3) MY157030A (US06465445-20021015-C00002.png)
NO (2) NO331022B1 (US06465445-20021015-C00002.png)
NZ (1) NZ508801A (US06465445-20021015-C00002.png)
PL (4) PL203343B1 (US06465445-20021015-C00002.png)
PT (4) PT2399582E (US06465445-20021015-C00002.png)
RU (1) RU2246947C2 (US06465445-20021015-C00002.png)
TR (5) TR200103455T2 (US06465445-20021015-C00002.png)
TW (2) TWI371279B (US06465445-20021015-C00002.png)
WO (1) WO1999063974A2 (US06465445-20021015-C00002.png)
ZA (1) ZA200007297B (US06465445-20021015-C00002.png)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CA2340343C (en) * 1998-08-14 2007-04-24 Schering Corporation Enantioselective synthesis
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
AR021719A1 (es) * 1998-12-18 2002-07-31 Schering Corp Composicion farmaceutica oral antiestrogenica.
JP5184727B2 (ja) 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
HU230543B1 (hu) 1999-07-06 2016-11-28 Endorecherche, Inc. Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
KR20020073566A (ko) * 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
JP4896335B2 (ja) * 2000-03-01 2012-03-14 ナームローゼ・フエンノートチヤツプ・オルガノン エストロゲン化合物としてのクロマン誘導体
WO2002003976A2 (en) * 2000-07-06 2002-01-17 Wyeth Combinations of bisphosphonates, estrogenic agents and optionally estrogens
MXPA02012890A (es) * 2000-07-06 2003-10-24 Wyeth Corp Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.
WO2002003988A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
FR2827764B1 (fr) * 2001-07-27 2005-08-19 Oreal Composition, notamment cosmetique, renfermant un steroide et un glycol
WO2003011282A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
US20040044226A1 (en) * 2001-10-15 2004-03-04 Dininno Frank P. Estrogen receptor modulators
ES2350446T3 (es) * 2002-04-24 2011-01-24 MERCK SHARP & DOHME CORP. Moduladores de los receptores de estrógenos.
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20050095241A1 (en) * 2003-08-26 2005-05-05 Vadlamudi Ratna K. Estrogen receptor modulators and uses thereof
EP2407462B1 (en) 2004-09-21 2014-07-30 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8941594B2 (en) * 2004-10-01 2015-01-27 Nvidia Corporation Interface, circuit and method for interfacing with an electronic device
CN106038572A (zh) * 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
JP5042209B2 (ja) 2005-03-24 2012-10-03 ノーラブズ エービー 酸化窒素による美容治療、前記治療を実施する装置、及びその製造方法
KR101505884B1 (ko) 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
CN101636372B (zh) 2007-02-14 2013-03-27 霍尔莫斯医疗有限公司 有治疗价值的三苯基丁烯衍生物的制备方法
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
WO2010107922A1 (en) * 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
WO2011156908A1 (en) * 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
ES2804263T3 (es) 2011-07-05 2021-02-05 Novan Inc Composiciones tópicas
HUE025350T2 (en) * 2011-07-19 2016-02-29 Pantarhei Bioscience Bv Tablets containing dehydroepiandrosterone (DHEA)
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
MD20140054A2 (ro) 2011-12-16 2014-10-31 Olema Pharmaceuticals, Inc. Compuşi noi de benzopiran, compoziţii şi utilizări ale acestora
CN102631677A (zh) * 2012-04-19 2012-08-15 中国农业大学 一种预防和/或治疗动脉粥样硬化的药物组合物
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CA2920110C (en) 2013-08-08 2022-05-31 Novan, Inc. Compositions and kits including a nitric oxide releasing compound and a hydrogel
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3166593B1 (en) 2014-07-11 2020-05-20 Novan, Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
GB201416186D0 (en) * 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
CA2974123C (en) 2015-02-02 2023-08-01 Mei Pharma, Inc. Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy
US10452661B2 (en) * 2015-06-18 2019-10-22 Microsoft Technology Licensing, Llc Automated database schema annotation
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR102319497B1 (ko) 2016-03-02 2021-11-01 노반, 인크. 염증 치료용 조성물 및 염증 치료 방법
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
BR112018070578A2 (pt) 2016-04-13 2019-02-12 Novan, Inc. composições, sistemas, kits, e métodos para tratar uma infecção
FR3052805B1 (fr) 2016-06-20 2020-06-26 Safran Aircraft Engines Disque aubage monobloc ameliore, partie tournante d'une turbomachine comprenant un tel disque et turbomachine associee
CN109224029A (zh) * 2018-09-30 2019-01-18 泓博元生命科技（深圳）有限公司 含有nmn的降血脂组合物、制剂及其制备方法与应用
US20220305030A1 (en) * 2019-10-03 2022-09-29 Caren Pharmaceuticals, Inc. Combination hormone formulations and therapies
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11858930B2 (en) 2020-07-28 2024-01-02 Jazz Pharmaceuticals Ireland Limited Fused bicyclic RAF inhibitors and methods for use thereof
WO2023156803A1 (en) * 2022-02-17 2023-08-24 Debreceni Egyetem Dhea-derived steroids
CN115554403B (zh) * 2022-08-16 2024-03-08 山东大学 类固醇激素dhea作为受体adgrg2激动剂配体的应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550107A (en) * 1895-11-19 Thirds to henry zervas and julius wegert
US536220A (en) * 1895-03-26 Puzzle
DK122125B (da) 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
US4496556A (en) 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
DE3590389T1 (de) 1984-08-02 1986-08-28 Schering Corp., Kenilworth, N.J. Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
JP2551590B2 (ja) * 1987-06-26 1996-11-06 株式会社リコー 複写機光学系の速度制御方法
JPS6440428A (en) 1987-08-07 1989-02-10 Daiichi Yakuhin Sangyo Kk Antihyperlipemia
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
HU208150B (en) 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5686465A (en) 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
WO1990006120A1 (en) 1988-12-01 1990-06-14 Schering Corporation Compositions for transdermal delivery of estradiol
US4920115A (en) * 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
IE62715B1 (en) 1989-03-10 1995-02-22 Endorecherche Inc Combination therapy for treatment of estrogen sensitive diseases
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
HUT64815A (en) 1992-09-04 1994-03-28 Berki An external correcting and fixing apparatus for treatment of fractures and defomities of bones as well as correcting unit preferably for external correcting and fixing units
US5354861A (en) 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
WO1994016709A2 (en) * 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
DE4401554A1 (de) 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
DK0635264T3 (da) 1993-06-24 1997-10-20 Lilly Co Eli Anti-østrogene 2-phenyl-3-aroylbenzothiazepiner som hypoglykæmiske midler
US5441964A (en) 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5391557A (en) 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5482950A (en) 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5418252A (en) 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
DK0654267T3 (da) * 1993-11-19 2002-05-13 Jenapharm Gmbh Carcinostatisk middel til hormonterapi indeholdende dienogest som aktiv komponent
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5425429A (en) * 1994-06-16 1995-06-20 Thompson; Michael C. Method and apparatus for forming lateral boreholes
US5681308A (en) 1994-06-24 1997-10-28 Stuart D. Edwards Ablation apparatus for cardiac chambers
NZ272608A (en) 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
EP0769946A4 (en) 1994-08-22 1997-11-05 Lilly Co Eli METHOD FOR MAINTAINING THE TEETH AND BONE IN THE ORAL AREA
IL115022A (en) 1994-08-22 2000-07-31 Lilly Co Eli Pharmaceutical compositions for inhibiting endometrial cancer
US5550123A (en) 1994-08-22 1996-08-27 Eli Lilly And Company Methods for inhibiting bone prosthesis degeneration
US5502074A (en) 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6399634B1 (en) 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US6703407B1 (en) 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US5637598A (en) 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
EP0794771A1 (en) 1994-11-29 1997-09-17 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
HUP9800521A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis
US5489587A (en) 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
US5571808A (en) 1995-01-31 1996-11-05 Eli Lilly And Company Method for treating smoking-related bone loss
US5552401A (en) 1995-02-28 1996-09-03 Eli Lilly And Company 2-benzyl-3-arylbenzothiophenes
US5523309A (en) 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
US5567828A (en) 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
ES2124064T3 (es) 1995-06-07 1999-01-16 Lilly Co Eli Compuestos y composiciones con cadenas laterales nitrogenadas no basicas.
IL124882A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of 3, 4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
WO1997025034A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
BR9708301A (pt) * 1996-02-14 1999-08-03 Hoechst Marion Roussel Inc Esteróides de 17-beta-ciclopropil (amino/óxi) 4-aza como inibidores ativos de 5-alfa-redutase e liase de c17-20 de testosterona
US6432982B1 (en) 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
EA000767B1 (ru) 1996-02-22 2000-04-24 Эли Лилли Энд Компани Бензотиофены, составы, их содержащие, и способы с их использованием
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
WO1997032837A1 (fr) 1996-03-06 1997-09-12 Sumitomo Pharmaceuticals Co., Ltd. Derives estrogenes non steroidiens
EP0801066A1 (en) 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
JP2000508643A (ja) * 1996-04-11 2000-07-11 エム． ロリア，ロジャー 腫瘍増殖のインヒビターとしての５―アンドロステン３β，１７αジオール
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
SK281737B6 (sk) 1996-04-19 2001-07-10 American Home Products Corporation 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
GB9616700D0 (en) * 1996-08-09 1996-09-25 Carey Beverly J Hormone supplement
CA2263175A1 (en) * 1996-08-28 1998-03-05 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation, and methods of use
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5861391A (en) * 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
WO1998034621A1 (en) * 1997-02-07 1998-08-13 Theratech, Inc. Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ZA985543B (en) * 1997-06-27 1998-12-28 Smithkline Beecham Corp Novel methods
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
EP1076558B1 (en) 1998-05-15 2003-07-16 Wyeth 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
HUP9900284A2 (hu) 1999-02-09 2001-02-28 János Váradi Háromfázisú, hidraulikus rugózó elem közúti és vasúti járművek számára
HU230543B1 (hu) 1999-07-06 2016-11-28 Endorecherche, Inc. Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
CN106038572A (zh) * 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
KR100944261B1 (ko) 2010-02-24
ZA200007297B (en) 2002-02-08
EP2386304A3 (en) 2011-12-07
CA2768828C (en) 2013-08-13
AR043075A1 (es) 2005-07-20
CN1636566A (zh) 2005-07-13
NO20006254L (no) 2001-02-01
EP1083905B1 (en) 2005-11-02
KR20090018227A (ko) 2009-02-19
JP2002517433A (ja) 2002-06-18
CA2768682A1 (en) 1999-12-16
EP1623712B1 (en) 2012-12-12
EP2399582B9 (en) 2014-09-10
CA2632567A1 (en) 1999-12-16
KR20090018226A (ko) 2009-02-19
EP1623712A3 (en) 2009-12-16
PT2386305E (pt) 2014-04-17
TR200103456T2 (tr) 2002-06-21
EP1623712A2 (en) 2006-02-08
KR20090016771A (ko) 2009-02-17
ES2399051T3 (es) 2013-03-25
US7943603B2 (en) 2011-05-17
CN1240388C (zh) 2006-02-08
ES2458218T9 (es) 2014-06-24
AU4253099A (en) 1999-12-30
TR200100551T2 (tr) 2001-07-23
NO331022B1 (no) 2011-09-12
DE69928104D1 (de) 2005-12-08
CA2768828A1 (en) 1999-12-16
KR20090018871A (ko) 2009-02-23
EP2386305B1 (en) 2014-02-12
US20070027122A1 (en) 2007-02-01
CA2768682C (en) 2014-03-18
HK1040367B (zh) 2006-09-29
EP2386305A3 (en) 2011-12-07
HK1040367A1 (en) 2002-06-07
HUP0103345A3 (en) 2002-11-28
WO1999063974A2 (en) 1999-12-16
CA2768773C (en) 2013-08-13
ES2463868T9 (es) 2014-06-24
ES2473040T3 (es) 2014-07-03
CA2334577C (en) 2008-08-05
TWI258369B (en) 2006-07-21
EP2386305A2 (en) 2011-11-16
US20040157812A1 (en) 2004-08-12
WO1999063974A3 (en) 2000-06-29
PL203704B1 (pl) 2009-11-30
HU1600307D0 (hu) 2002-02-28
MY125047A (en) 2006-07-31
PL199798B1 (pl) 2008-10-31
PL345887A1 (en) 2002-01-14
DK2386304T3 (da) 2014-05-12
US7884092B2 (en) 2011-02-08
HUP0103345A2 (hu) 2002-02-28
TR200103455T2 (tr) 2002-06-21
US6465445B1 (en) 2002-10-15
EP2386304B9 (en) 2014-11-05
MY157030A (en) 2016-04-15
ES2458218T3 (es) 2014-04-30
ES2253922T3 (es) 2006-06-01
HU230495B1 (hu) 2016-09-28
TW200810763A (en) 2008-03-01
IL140178A (en) 2008-07-08
DE69928104T2 (de) 2006-08-24
EP2386304B1 (en) 2014-03-19
NO20006254D0 (no) 2000-12-08
KR20010052763A (ko) 2001-06-25
ATE308326T1 (de) 2005-11-15
MY151187A (en) 2014-04-30
CA2768882A1 (en) 1999-12-16
EP2399582A1 (en) 2011-12-28
NO332187B1 (no) 2012-07-23
TR200103453T2 (tr) 2002-06-21
EP2399582B1 (en) 2014-03-26
PT1623712E (pt) 2013-02-13
US7429576B2 (en) 2008-09-30
US8188066B2 (en) 2012-05-29
EP2386304A2 (en) 2011-11-16
RU2246947C2 (ru) 2005-02-27
TR200103454T2 (tr) 2002-06-21
NZ508801A (en) 2003-08-29
EP1083905A2 (en) 2001-03-21
DK1623712T3 (da) 2013-01-21
JP2007191484A (ja) 2007-08-02
CY1115317T1 (el) 2017-01-04
CN1312718A (zh) 2001-09-12
CY1113712T1 (el) 2016-06-22
IL185087A0 (en) 2007-12-03
TWI371279B (en) 2012-09-01
CY1115231T1 (el) 2017-01-04
CY1115069T1 (el) 2016-12-14
PL195772B1 (pl) 2007-10-31
CA2334577A1 (en) 1999-12-16
DK2386305T3 (da) 2014-04-14
US20070027124A1 (en) 2007-02-01
PL203343B1 (pl) 2009-09-30
CA2768841C (en) 2013-08-13
EP2386305B9 (en) 2014-12-17
BR9911116A (pt) 2001-02-28
DK2399582T3 (da) 2014-07-07
CA2768882C (en) 2015-01-27
US20070027123A1 (en) 2007-02-01
US6670346B1 (en) 2003-12-30
PT2386304E (pt) 2014-05-26
DK1083905T3 (da) 2006-03-20
MXPA00012306A (es) 2003-07-28
CA2768841A1 (en) 1999-12-16
KR20090018870A (ko) 2009-02-23
PT2399582E (pt) 2014-06-25
JP2013049703A (ja) 2013-03-14
CA2632567C (en) 2012-04-10
NO20092730L (no) 2001-02-01
IL140178A0 (en) 2002-02-10
ES2463868T3 (es) 2014-05-29
CA2768773A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
ID28696A (id) Penggunaan medis suatu modulator reseptor estrogen selektif dalam kombinasi dengan prekursor-prekursor steroid kelamin
NO20023484L (no) Selektive östrogenreseptormodulatorer i kombinasjon med östrogener
HUP0204029A3 (en) Triphenylalkene derivatives and their use as selective estrogen receptor modulators
HK1043788A1 (zh) 四環黃體酮受體調節劑化合物及方法
CY2009015I1 (el) Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο
IL154425A0 (en) Selective androgen receptor modulators and methods of use thereof
NO20020912L (no) Bicykliske androgen- og progesteronreseptorer- modulatorforbindelser og fremgangsmåter
DK0938368T3 (da) Integreret knoglecementblande- og dispenseringssystem
PL340623A1 (en) Oral contraceptive agents containing antistrogen and progestin
PT1216046E (pt) Nova combinacao de loteprednol e anti-histaminicos
MXPA01011294A (es) Compuestos moduladores de receptor de progesterona tetraciclicos y metodos.
DE29610683U1 (de) Toilettenpapier mit Befeuchtung und Toilettenpapierspender zur Abgabe desselben
GB9420036D0 (en) Flushing device of toilet
DE69908592T2 (de) Kontinuierliche Misch- und Zuführvorrichtung
TWI293247B (en) Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors (2)
DE29615834U1 (de) Doppel-Einhebel-Wannen-Füll und Brause-Armatur
SI1235776T1 (sl) Trifenilalkenski derivati in njihova uporaba kot selektivni estrogenski receptorski modulatorji
DE29700884U1 (de) Hygienegerät zum Einsatz in Toiletten
BR9502979A (pt) Manta higiênica flexivel e descartável para assento em vasos sanitários
IT238335Y1 (it) Scopino igienico usa-e-getta
HU9800209V0 (en) Multilayer and reusable higienic water-closet seat
FR2774282B3 (fr) Urinaux a usage medical et paramedical concus et equipes pour une utilisation parfaitement hygienique
PL56385Y1 (en) Lavatory bowl flushing device
KR970049011U (ko) 일회용 변기 깔게
KR970039435U (ko) 변기용 세정수 공급장치 구조